Literature DB >> 20212427

Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.

Cristina Sampaio, Joaquim J Ferreira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20212427     DOI： 10.1038/nrneurol.2010.2

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

Review 1.  Treatment interventions for Parkinson's disease: an evidence based assessment.

Authors:  Olivier Rascol; Christopher Goetz; William Koller; Werner Poewe; Cristina Sampaio
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

2.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Authors: 
Journal:  Arch Neurol       Date:  2004-04

3.  Slowing the progression of Alzheimer disease: methodologic issues.

Authors:  P Leber
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  The delayed-start study design.

Authors:  Ralph B D'Agostino
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

Review 5.  Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.

Authors:  Silvia Mandel; Orly Weinreb; Tamar Amit; Moussa B H Youdim
Journal:  Brain Res Brain Res Rev       Date:  2005-04

6.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Authors:  C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

7.  Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Authors:  Robert A Hauser; Mark F Lew; Howard I Hurtig; William G Ondo; Joanne Wojcieszek; Cheryl J Fitzer-Attas
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

8.  Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.

Authors:  Kenneth Marek; Danna Jennings; Gilles Tamagnan; John Seibyl
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

Review 9.  Monoamine oxidase B inhibitors for early Parkinson's disease.

Authors:  A D Macleod; C E Counsell; N Ives; R Stowe
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20
  9 in total
  6 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

2.  Discordant effects of rasagiline doses in Parkinson disease.

Authors:  Spyros N Deftereos; Christos A Andronis
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

3.  Tapping natural reservoirs of homing endonucleases for targeted gene modification.

Authors:  Ryo Takeuchi; Abigail R Lambert; Amanda Nga-Sze Mak; Kyle Jacoby; Russell J Dickson; Gregory B Gloor; Andrew M Scharenberg; David R Edgell; Barry L Stoddard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-22       Impact factor: 11.205

4.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

5.  MAO-inhibitors in Parkinson's Disease.

Authors:  Peter Riederer; Gerd Laux
Journal:  Exp Neurobiol       Date:  2011-03-31       Impact factor: 3.261

Review 6.  Disease modification and Neuroprotection in neurodegenerative disorders.

Authors:  Jeffrey Cummings
Journal:  Transl Neurodegener       Date:  2017-09-26       Impact factor: 8.014
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.